Abstract
This Patent Highlight presents a detailed analysis of three novel classes of compounds designed to inhibit multiple forms of the K-Ras protein, as described in three patent applications. These patents cover macrocyclic compounds, peptidomimetics, and pyridopyrimidine inhibitors. This work explores each invention's design, mechanism of action, relevance to cancer treatment, and results from assays demonstrating the efficacy of these compounds. The findings highlight the significant potential of these compounds in inhibiting tumor growth and inducing apoptosis in cancer cells, offering promising therapeutic options for K-Ras-driven cancers.